Amended Statement of Ownership (sc 13g/a)
14 Février 2023 - 10:02PM
Edgar (US Regulatory)
Securities
and Exchange Commission
Washington,
DC 20549
SCHEDULE 13G/A
Under
the Securities Exchange Act of 1934
(Amendment No.
1)*
ASLAN Pharmaceuticals
Limited
(Name of Issuer)
Ordinary Shares as represented by American
Depository Shares (“ADSs”),
par value $0.01 per ordinary share**
(Title of Class of Securities)
04522R101***
(CUSIP Number)
December 31, 2022
(Date of Event Which Requires Filing of This Statement)
Check the appropriate box to designate the rule
pursuant to which this Schedule is filed:
o Rule
13d-1(b)
ý Rule
13d-1(c)
o Rule
13d-1(d)
*The remainder of this cover page shall be filled
out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent
amendment containing information which would alter the disclosures provided in a prior cover page.
**Ordinary Shares are not for trading, but only
in connection with the registration of the ADSs.
***CUSIP number assigned to the ADSs of the Company.
Each ADS represents five Ordinary Shares.
The information required in the remainder of this
cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
|
CUSIP No. 04522R101
|
13G/A |
Page 2 of 8 Pages |
| 1 |
NameS of
Reporting Persons
I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)
TANG CAPITAL
PARTNERS, LP
|
| 2 |
Check the Appropriate Box if a Member of a Group* (a) ¨
(b) ý |
| 3 |
SEC Use Only
|
| 4 |
Citizenship
or Place of Organization
DELAWARE
|
|
Number
of |
5 |
Sole Voting
Power
0
|
|
Shares
BENEFICIALLY
Owned by |
6 |
Shared Voting
Power
26,824,625 |
Each Reporting
Person with |
7 |
Sole Dispositive
Power
0
|
| |
8 |
Shared Dispositive
Power
26,824,625
|
| 9 |
Aggregate
Amount Beneficially Owned by each Reporting Person
26,824,625
|
| 10 |
Check Box
if the Aggregate Amount in Row (9) excludes certain shares
¨ |
| 11 |
Percent of
Class represented by amount in row 9
7.8%
|
| 12 |
type of reporting
person
pN
|
| |
|
|
|
|
|
|
CUSIP No. 04522R101
|
13G/A |
Page 3 of 8 Pages |
| 1 |
NameS of
Reporting Persons
I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)
Tang Capital
Management, LLC
|
| 2 |
Check the Appropriate Box if a Member of a Group* (a) ¨
(b) ý |
| 3 |
SEC Use Only
|
| 4 |
Citizenship
or Place of Organization
DELAWARE
|
|
Number
of |
5 |
Sole Voting
Power
0
|
|
Shares
BENEFICIALLY
Owned by |
6 |
Shared Voting
Power
26,824,625 |
Each Reporting
Person with |
7 |
Sole Dispositive
Power
0
|
| |
8 |
Shared Dispositive
Power
26,824,625
|
| 9 |
Aggregate
Amount Beneficially Owned by each Reporting Person
26,824,625
|
| 10 |
Check Box
if the Aggregate Amount in Row (9) excludes certain shares
¨ |
| 11 |
Percent of
Class represented by amount in row 9
7.8%
|
| 12 |
type of reporting
person
OO
|
| |
|
|
|
|
|
|
CUSIP No. 04522R101
|
13G/A |
Page 4 of 8 Pages |
| 1 |
NameS of
Reporting Persons
I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)
Kevin Tang
|
| 2 |
Check the Appropriate Box if a Member of a Group* (a) ¨
(b) ý |
| 3 |
SEC Use Only
|
| 4 |
Citizenship
or Place of Organization
united states
|
|
Number
of |
5 |
Sole Voting
Power
0
|
|
Shares
BENEFICIALLY
Owned by |
6 |
Shared Voting
Power
26,824,625 |
Each Reporting
Person with |
7 |
Sole Dispositive
Power
0
|
| |
8 |
Shared Dispositive
Power
26,824,625
|
| 9 |
Aggregate
Amount Beneficially Owned by each Reporting Person
26,824,625
|
| 10 |
Check Box
if the Aggregate Amount in Row (9) excludes certain shares
¨ |
| 11 |
Percent of
Class represented by amount in row 9
7.8%
|
| 12 |
type of reporting
person
IN
|
| |
|
|
|
|
|
| Item 1(a). | Name of Issuer: |
ASLAN Pharmaceuticals Limited,
a Delaware corporation (the “Issuer”)
| Item 1(b). | Address of Issuer’s Principal Executive Offices: |
83 Clemenceau Avenue #12-03
UE Square, Singapore 239920
| Item 2(a). | Name of Person Filing: |
This Statement on Schedule
13G (this “Statement”) is filed by Tang Capital Partners, LP (“Tang Capital Partners”); Tang Capital Management,
LLC, the general partner of Tang Capital Partners (“Tang Capital Management”); and Kevin Tang, the manager of Tang Capital
Management.
| Item 2(b). | Address of Principal Business Office or, if none, Residence: |
4747 Executive Drive, Suite 210,
San Diego, CA 92121
Tang Capital Partners is
a Delaware limited partnership. Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen.
| Item 2(d). | Title of Class of Securities: |
Ordinary Shares, par value $0.01 per share,
represented by ADSs (the “Ordinary Shares”)
| Item 2(e). | CUSIP number 04522R101 has been assigned to the ADSs of the Company. Each ADS represents five Ordinary Shares. |
| (a) | Amount Beneficially Owned: |
Tang Capital Partners. Tang Capital
Partners beneficially owns 26,824,625 Ordinary Shares of the Issuer, in the form of
5,364,925 ADSs.
Tang Capital Partners shares voting and dispositive
power over such shares with Tang Capital Management and Kevin Tang.
Tang Capital Management. Tang Capital Management
beneficially owns 26,824,625 Ordinary Shares of the Issuer, in the form of 5,364,925 ADSs.
Tang Capital Management shares voting and
dispositive power over such shares with Tang Capital Partners and Kevin Tang.
Kevin Tang. Kevin Tang beneficially owns 26,824,625
Ordinary Shares of the Issuer, in the form of 5,364,925 ADSs.
Kevin Tang shares voting and dispositive
power over such shares with Tang Capital Partners and Tang Capital Management.
The percentages used herein are based on 344,042,734
Ordinary Shares outstanding as of August 16, 2022, as set forth in the Issuer’s Prospectus filed pursuant to Rule 424(b)(5) that
was filed with the Securities and Exchange Commission on September 13, 2022.
| Tang Capital Partners |
7.8% |
| Tang Capital Management |
7.8% |
| Kevin Tang |
7.8% |
| (c) | Number of shares as to which such person has: |
| (i) | sole power to vote or to direct the vote: |
| Tang Capital Partners |
0 shares |
| Tang Capital Management |
0 shares |
| Kevin Tang |
0 shares |
| (ii) | shared power to vote or to direct the vote: |
| Tang Capital Partners |
26,824,625
shares |
| Tang Capital Management |
26,824,625 shares |
| Kevin Tang |
26,824,625 shares |
| (iii) | sole power to dispose or to direct the disposition of: |
| Tang Capital Partners |
0 shares |
| Tang Capital Management |
0 shares |
| Kevin Tang |
0 shares |
| (iv) | shared power to dispose or to direct the disposition of: |
| Tang Capital Partners |
26,824,625
shares |
| Tang Capital Management |
26,824,625 shares |
| Kevin Tang |
26,824,625 shares |
| Item 5. | Ownership of Five Percent or Less of a Class. |
If
this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner
of more than five percent of the class of securities, check the following: ¨
| Item 6. | Ownership of More than Five Percent on Behalf of Another Person. |
Not applicable
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the
Parent Holding Company. |
Not applicable.
| Item 8. | Identification and Classification of Members of the Group. |
Not applicable.
| Item 9. | Notice of Dissolution of Group. |
Not applicable.
By signing below I certify that, to the
best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect
of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as
a participant in any transaction having that purpose or effect.
Signature
After reasonable inquiry and to the best of my knowledge
and belief, I certify that the information set forth in this statement is true, complete and correct.
| Date: |
February
14, 2023 |
|
| |
|
| |
|
| TANG CAPITAL PARTNERS, LP |
| |
|
| By: |
Tang Capital Management, LLC, its General Partner |
| |
|
| |
|
| By: |
/s/ Kevin Tang |
|
| |
Kevin Tang, Manager |
| |
|
| |
|
| TANG CAPITAL MANAGEMENT, LLC |
| |
|
| |
|
| By: |
/s/ Kevin Tang |
|
| |
Kevin Tang, Manager |
| |
|
| |
|
| /s/ Kevin Tang |
|
| Kevin Tang |
Page 8 of 8
ASLAN Pharmaceuticals (NASDAQ:ASLN)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
ASLAN Pharmaceuticals (NASDAQ:ASLN)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
